scispace - formally typeset
G

Gilles Pagès

Researcher at French Institute of Health and Medical Research

Publications -  403
Citations -  25339

Gilles Pagès is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Quantization (signal processing) & MAPK/ERK pathway. The author has an hindex of 73, co-authored 398 publications receiving 22584 citations. Previous affiliations of Gilles Pagès include Paul Sabatier University & French Institute for Research in Computer Science and Automation.

Papers
More filters
Journal ArticleDOI

Recursive computation of the invariant distributions of Feller processes: Revisited examples and new applications

TL;DR: In this paper, the abstract framework developed in [G. Pages and C. Rey, Recursive computation of the invariant distribution of Markov and Feller processes, preprint 2017, https://arxiv.1703.04557] was used to build invariant distributions for Brownian diffusion processes using the Milstein scheme and for diffusion processes with censored jump using the Euler scheme.
Posted Content

Quantization and martingale couplings

TL;DR: In this paper, it was shown that quantization provides a natural way to preserve the convex order when approximating two ordered probability measures by two finitely supported ones, and that the quantization errors correspond to martingale couplings between each original probability measure and its quantization.
Posted Content

New approach to greedy vector quantization

TL;DR: It is shown, for a more general class of distributions satisfying a certain control, that the quantization error of these sequences have an n − 1 d rate of convergence and that the distortion mis-match property is satisfied.
Posted Content

Recursive marginal quantization of the Euler scheme of a diffusion process

TL;DR: A new approach to quantize the marginals of the discrete Euler diffusion process by reducing dramatically the computational complexity of the search of optimal quantizers while increasing their computational precision with respect to the algorithms commonly proposed in this framework.
Journal ArticleDOI

Contrasted effects of the multitarget TKi vandetanib on docetaxel-sensitive and docetaxel-resistant prostate cancer cell lines.

TL;DR: T tumor analyses revealed overexpression of the EGFR/VEGFR pathways in PC3R relative to PC3wt, and results suggest that vandetanib should not be associated with docetaxel in treatment-naive or docetAXel-resistant prostate cancer (CaP).